Company profile for Reistone Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Reistone Biopharma Company Limited is a clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory diseases with unmet medical needs. Developing therapies for diseases requires new approaches and strong collaboration between scientists, industry, regulatory agencies and patient groups. Reistone is forged from the company's close collaborations with key stakeholders and leading pharma...
Reistone Biopharma Company Limited is a clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory diseases with unmet medical needs. Developing therapies for diseases requires new approaches and strong collaboration between scientists, industry, regulatory agencies and patient groups. Reistone is forged from the company's close collaborations with key stakeholders and leading pharmaceutical companies, and is dedicated to transforming new biotechnology insights into breakthrough medicine for significant unmet medical needs in China as well globally.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Room 203, 2F, Xiangke Road, Zhangjiang Hi-Tech Park, Pudong,Shanghai, 201210
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://scrip.pharmaintelligence.informa.com/SC146406/Small-Molecules-Attract-Investors-As-Two-Chinese-Biotechs-Bag-$161m

Dexter Yan SCRIP
19 May 2022

https://www.clinicaltrialsarena.com/news/reistone-atopic-dermatitis-trial/

CLINICALTRIALSARENA
12 Oct 2021

https://www.prnewswire.com/news-releases/reistone-announces-positive-results-from-a-phase-ii-study-evaluating-shr0302-ointment-for-patients-with-mild-to-moderate-atopic-dermatitis-301396652.html

PRNEWSWIRE
11 Oct 2021
Immunocore's bispecific gets speedy review with FDA, EMA; Xalud grabs $30M
Immunocore's bispecific gets speedy review with FDA, EMA; Xalud grabs $30M

24 Aug 2021

// Paul Schloesser\nMax Gelman\nAmber Tong ENDPTS

https://endpts.com/immunocores-bispecific-lands-speedy-review-with-fda-ema-low-profile-gene-therapy-player-grabs-30m/

Paul Schloesser\nMax Gelman\nAmber Tong ENDPTS
24 Aug 2021

https://www.prnewswire.com/news-releases/reistone-announces-positive-topline-phase-2-results-for-shr0302-a-selective-jak1-inhibitor-for-treatment-of-patients-with-alopecia-areata-301360967.html

PRNEWSWIRE
24 Aug 2021

https://www.prnewswire.com/news-releases/reistone-announces-first-patient-dosed-in-phase-iii-global-study-in-atopic-dermatitis-301290192.html

PRNEWSWIRE
13 May 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty